Neurocrine Biosciences Stocks List
|NBIX||F||Neurocrine Biosciences, Inc.||-6.32|
|SPRB||F||Spruce Biosciences, Inc.||0.05|
|FBT||F||First Trust Amex Biotech Index Fund||3.46|
|BBP||D||BioShares Biotechnology Products Fund||2.33|
|BBH||D||Market Vectors Biotech ETF||2.16|
|LABD||F||Direxion Daily S&P Biotech Bear 3X Shares||1.62|
|BIS||D||ProShares UltraShort Nasdaq Biotechnology||1.16|
View all Neurocrine Biosciences related ETFs...
Neurocrine Biosciences is a publicly traded biopharmaceutical company founded in 1992. The company is headquartered in San Diego, California, and led by CEO Kevin Gorman. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids.